Sera Prognostics, Inc. (SERA)

Market Cap	86.15M +3.0%
Revenue (ttm)	57,000 -50.4%
Net Income	-32.14M
EPS	-0.65
Shares Out	39.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,110
Open	2.170
Previous Close	2.150
Day's Range	2.000 - 2.276
52-Week Range	1.370 - 4.090
Beta	0.93
Analysts	Strong Buy
Price Target	5.00 (+127.27%)
Earnings Date	May 6, 2026

About SERA

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive an...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: SERA
• Website: https://www.sera.com

Financial Performance

In 2025, Sera Prognostics's revenue was $81,000, an increase of 5.19% compared to the previous year's $77,000. Losses were -$31.93 million, -2.95% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for SERA stock is "Strong Buy." The 12-month stock price target is $5.0, which is an increase of 127.27% from the latest price.

Price Target

$5.0

(127.27% upside)

Analyst Consensus: Strong Buy